Mitsubishi UFJ Asset Management
LXEO icon

Mitsubishi UFJ Asset Management’s Lexeo Therapeutics LXEO Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233K Buy
49,988
+24,411
+95% +$132K ﹤0.01% 1007
2026
Q1 		$147K Sell
25,577
-632
-2% -$4.48K ﹤0.01% 1016
2025
Q4 		$252K Buy
+26,209
New +$239K ﹤0.01% 982

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Mitsubishi UFJ Asset Management's LXEO Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management increased its Lexeo Therapeutics (LXEO) stake by 95% in Q2 2026, buying an estimated $132K and bringing the position to 49,988 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #1007.

Mitsubishi UFJ Asset Management first reported a position in LXEO in Q4 2025 and has held it in 3 quarters since. The position peaked at $252K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 49,988 shares of Lexeo Therapeutics worth $233K as of Q2 2026.
  • Mitsubishi UFJ Asset Management bought 24,411 Lexeo Therapeutics shares in Q2 2026, an estimated $132K.
  • Lexeo Therapeutics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #1007 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Mitsubishi UFJ Asset Management's Lexeo Therapeutics position peaked at $252K in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.